CHERYL LUMMIS: Open Payments
NPI 1962438762 · MEXICO, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,037 in 64 payments from 17 companies in 2025. Trend: 2023 $872 · 2024 $1,140 · 2025 $1,037
Food & beverage: $1,037
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $213 |
| AstraZeneca Pharmaceuticals LP | 4 | $140 |
| Teva Pharmaceuticals USA, Inc. | 16 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $98 |
| Lundbeck LLC | 5 | $96 |
| ABBVIE INC. | 5 | $85 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Corcept Therapeutics | 2 | $30 |
| Viatris Specialty LLC | 1 | $24 |
Products named: INGREZZA, REXULTI, AIRSUPRA, CAPLYTA, AUSTEDO XR, VRAYLAR, UZEDY, FANAPT.
Industry payments across MO — which companies pay providers there.
